Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuFlu vs BuCy2 Conditioning for AML
NCT01191957Phase 3Completed
- Sponsor
- GITMO
- Start
- Jan 2008
- Primary completion
- Dec 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of fludarabine in acute myeloid leukemia (AML), sponsored by GITMO. Primary endpoint: Transplant-Related Mortality at 1 year. Started Jan 2008; status: completed.
02
Drugs
fludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01191957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191957.